For the quarter ending 2026-03-31, ABUS made $179,126K in revenue. $169,598K in net income. Net profit margin of 94.68%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 179,126 | 1,051 | 529 | 10,739 |
| Research and development | 4,120 | 5,006 | 5,778 | 5,498 |
| General and administrative | 5,889 | 3,689 | 3,044 | 3,328 |
| Change in fair value of contingent consideration | 209 | -2,657 | 268 | 260 |
| Restructuring costs | 0 | 303 | 98 | 165 |
| Total operating expenses | 10,218 | 6,341 | 9,188 | 9,251 |
| Income (loss) from operations | 168,908 | -5,290 | -8,659 | 1,488 |
| Interest income | 815 | 877 | 952 | 1,042 |
| Gain on sale of property and equipment | - | 674 | - | - |
| Interest expense | 17 | 18 | 23 | 28 |
| Foreign exchange (loss) gain | -11 | 1 | -12 | 21 |
| Total other income | 787 | 1,534 | 917 | 1,035 |
| Net income (loss) | 169,695 | -3,756 | -7,742 | 2,523 |
| Unrealized gain on available-for-sale securities | - | 31 | - | - |
| Unrealized loss on available-for-sale securities | -97 | - | 58 | -21 |
| Comprehensive income (loss) | 169,598 | -3,725 | -7,684 | 2,502 |
| Basic EPS | 0.88 | -0.019 | -0.04 | 0.01 |
| Diluted EPS | 0.87 | -0.019 | -0.04 | 0.01 |
| Basic Average Shares | 193,768,641 | 192,361,083 | 191,778,950 | 191,551,282 |
| Diluted Average Shares | 195,214,067 | 191,512,632 | 191,778,950 | 192,399,733 |
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)